Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Cepheid history
Cepheid company history timeline
MARCH Company incorporated in the State of California on 4 March 1996
One year after he left NovaSensor, he collaborated with Gutshall and Northrup to form Cepheid in August 1996, a company that operated in virtual anonymity for the first five years of its existence.
Cepheid was founded in 1996 with a vision to develop an innovative system that simplified a highly complex, multi-stage process for the detection and analysis of nucleic acids, such as DNA, in samples such as blood, urine, food and industrial water.
In 1998, revenue totaled $3.5 million, a volume matched the following year, but losses during the two years eclipsed $11 million.
Living largely off funding from government agencies, the company labored to bring its first product to market, a device dubbed the SmartCycler that debuted in May 2000, four years after the company was incorporated.
The system was launched in 2000, the same year the Company went public.
2000 The company first product, the SmartCycler, is released.
The company’s focus temporarily shifted following the terrorist attacks in 2001.
During the 2001 anthrax attacks, United States federal agencies contracted with Cepheid to track the anthrax.
When Bishop joined the company, the hopes for future profitability were pinned on the success of the company's next-generation device dubbed GeneXpert, a test version of which was delivered to the United States Army Medical Research Institute of Infectious Diseases in early 2002.
Cepheid's leadership changed during this period, as Gutshall passed the reins of command in 2002 to John L. Bishop, who had spent the previous decade serving as president of Vysis, a genomic disease management company.
2002 Cepheid, as part of partnership led by Northrop-Grumman Corp., is awarded a pre-production contract with the United States Postal Service to install biodetection units at 14 mail-sorting facilities.
In 2003, the company put a temporary hold on some healthcare development to work with defense contractor, Northrop Grumman, on a United States federal government contract to install anthrax detection systems at US Post Office sites nationwide.
At the heart of the company's biodetection units was the company's GeneXpert technology, a comprehensive DNA analysis system that made its commercial debut in the company's third fiscal quarter of 2004.
Cepheid won the 2006 Industrial Design Excellence Awards for its product, Reagent Bead Dispenser.
The first clinical application for the GeneXpert System was introduced in 2006 with the United States FDA clearance of XpertGBS, a rapid molecular diagnostic test for Group B Streptococcus in expectant women.
In 2010, the World Health Organization endorsed our newly introduced Tuberculosis test, Xpert MTB/RIF as a “game-changer for TB and MDR-TB care delivery.”
In 2012, Cepheid won a contract with the United States Department of Veterans Affairs for its MRSA reagent test kits.
As of March 31, 2014, Cepheid markets 14 United States FDA-cleared clinical in vitro diagnostic (IVD) tests in the United States and 16 IVD tests internationally and has placed 6,012 GeneXpert systems globally.
In 2015, the Company announced its intention to develop tests for the Oncology market as well as plans for its newest system innovation: the GeneXpert Omni.
Targeted for physician office and other near-patient applications, the connected and portable GeneXpert Omni debuted in late 2019, in ex-United States territories.
As of March 2020, there are over 23 000 GeneXpert machines globally, 7000 - 10,000 of them in Africa, Latin America and South-East Asia, with over a hundred in some African countries, due to long-term investment in tuberculosis-testing infrastructure by The Global Fund, among others.
In March 2020, the company announced a rapid diagnostic test for SARS-CoV-2; the United States FDA granted an emergency use authorization for the test.
Rate Cepheid's efforts to communicate its history to employees.
Cepheid jobs
Do you work at Cepheid?
Is Cepheid's vision a big part of strategic planning?
Cepheid competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Seagen | 1997 | $2.0B | 900 | - |
| Gilead Sciences | 1987 | $28.8B | 11,800 | 753 |
| Regeneron | 1988 | $14.2B | 9,123 | 366 |
| Foundation Medicine | 2010 | $152.9M | 1,300 | 47 |
| Sarepta Therapeutics | 1980 | $1.9B | 840 | 25 |
| Sanofi Genzyme | 1981 | $4.6B | 12,000 | - |
| Human Genome Sciences | 1992 | $131.0M | 1,000 | - |
| Merck | 1891 | $64.2B | 74,000 | 1,771 |
| Vertex Pharmaceuticals | 1989 | $11.0B | 3,400 | 301 |
| Agilent Technologies | 1999 | $6.5B | 13,500 | 179 |
Cepheid history FAQs
Zippia gives an in-depth look into the details of Cepheid, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Cepheid. The employee data is based on information from people who have self-reported their past or current employments at Cepheid. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Cepheid. The data presented on this page does not represent the view of Cepheid and its employees or that of Zippia.
Cepheid may also be known as or be related to CEPHEID, Cepheid, Cepheid Inc and Cepheid Inc.